IBJNews

Lilly, other drugmakers to keep paying doctors

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co., Pfizer Inc., Sanofi and other large drugmakers will keep paying doctors to give talks about their products, leaving GlaxoSmithKline Plc alone for now in its decision to halt such compensation.

Glaxo changed its policy after Chinese authorities accused the company of using cash and sexual favors to bribe doctors and health officials to promote product sales. The company’s competitors say physicians often remain the best source of information for their colleagues and should be rewarded for their work.

The industry is facing greater scrutiny about fees to doctors after paying at least $12.9 billion in fines and settlements in the U.S. alone since 2009, mostly over improper marketing, according to the U.S. Justice Department.

Ensuring transparency for physician compensation among the companies that continue the practice is paramount, said Nikos Dedes, a member of the management board of the European Medicines Agency and founder of Greek HIV patient advocacy group Positive Voice.

“This should happen in a much faster manner,” Dedes said in a telephone interview from Athens. “There should be some pressure.”

Doctors prefer to learn about treatment options from their peers, and payments make sense given the time and energy required to understand and share information, according to companies that plan to keep remunerating physicians.

Fair compensation

“Few products in the world are as complex as an innovative medicine,” said Scott MacGregor, a spokesman for Indianapolis-based Lilly. Glaxo’s move won’t change how Lilly does business, MacGregor said.

Work done by health-care professionals “needs to be compensated in a fair and transparent manner,” according to Paris-based Sanofi.

Pfizer, the world’s biggest drugmaker, is “committed to fairly compensating health-care professionals, clinical investigators and institutions for the work they do,” Dean Mastrojohn, a spokesman for the company, said in an e-mail.

Bristol-Myers Squibb Co., based in New York like Pfizer, said it properly compensates physicians for their time. The company supports “appropriate efforts to increase transparency.”

Dublin-based Shire Plc, the biggest maker of drugs for attention-deficit disorder, said “we appropriately compensate” physicians and researchers for their expertise.

The industry has taken steps toward disclosure this year. Drugmakers who belong to the European Federation of Pharmaceutical Industries and Associations, which include Sanofi, Lilly, Bristol-Myers and Pfizer, are being pushed to report payments under a rule set this year by the trade group.

Dollars for docs

The European rule gives drugmakers until 2016 to disclose payments for the first time from the preceding year.

In the U.S., the Patient Protection and Affordable Care Act of 2010 required companies to track payments starting Aug. 1, and report the information to the government for annual publication starting next year.

Some drugmakers are already publishing data for the U.S., in some cases because of settlement deal requirements. ProPublica, a not-for-profit investigative news organization, tracks that data in a project called Dollars for Docs. It shows that Glaxo had already pared back its payments.

Glaxo said in 2011 it changed its U.S. marketing practices by eliminating individual sales goals, after facing government investigations over its marketing of diabetes drug Avandia and other medicines. It settled those claims in 2012 by paying a record $3 billion, only to face allegations of bribery last summer in China. The London-based company said earlier this week it would abolish individual sales goals worldwide by 2015.

Exceeding Pfizer

Glaxo’s spending on speaking fees dropped more than 80 percent from 2010 to about $2.5 million in each of the first three quarters of last year, according to ProPublica.

That’s more than the $2.08 million per quarter spent by Pfizer. Lilly spent $5.94 million per quarter on speaking fees per quarter in the same 2012 time period.

By way of comparison, Merck & Co. spent $4.81 million, and AstraZeneca Plc paid $4.06 million.

Neither company answered calls and e-mails seeking comment.

Bayer AG, Roche Holding AG and Novartis AG didn’t comment on whether they planned to follow Glaxo’s lead. Bayer of Leverkusen, Germany, said in a statement the company abides by the law and guidelines laid out by its trade associations.

“We’re observing these developments very closely,” said Daniel Grotzky, a spokesman for Basel, Switzerland-based Roche. “Obviously the overall trend is toward more transparency.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT